Tests a heart care plan for COVID-19 survivors at risk of heart failure
Tests a heart care plan in COVID-19 survivors over 50 with reduced fitness.
Plain-language title generated from the registry record
Registry title: Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)
Key facts
- Where
- Melbourne, AustraliaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT04983823, who can take part
Where in Australia
- Baker Heart and Diabetes InstituteMelbourne, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Baker Heart and Diabetes Institute
- Trial code
- NCT04983823
- Record updated
- 3 October 2025
- Original description
This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors >50 years old.Read full original descriptionShow less
Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure
This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors >50 years old.
The overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.
Inclusion: History of COVID-19 infection; Live within a geographically accessible area for follow-up.
Exclusion: History of previous heart failure (baseline New York Heart Association (NYHA) classification >2); Contraindications to beta blockers or angiotensin-converting enzyme inhibitors; Oncologic (or other) life expectancy <12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial; Already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both; Mobility impairment that would impact participants' ability to perform exercise; Valvular stenosis or regurgitation of >moderate severity; Inability to acquire interpretable images (identified from baseline echo); Unable to provide written informed consent to participate in this study.